Literature DB >> 30354516

Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.

Brian Claggett1, John M Lachin2, Stefan Hantel3, David Fitchett4,5, Silvio E Inzucchi6, Hans J Woerle7, Jyothis T George7, Bernard Zinman5,8.   

Abstract

Entities:  

Keywords:  cardiovascular diseases; diabetes mellitus; empagliflozin

Mesh：

Substances：

Year:  2018        PMID： 30354516     DOI： 10.1161/CIRCULATIONAHA.118.033810

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  12 in total

1.  Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.

Authors:  Muthiah Vaduganathan; Silvio E Inzucchi; Naveed Sattar; David H Fitchett; Anne Pernille Ofstad; Martina Brueckmann; Jyothis T George; Subodh Verma; Michaela Mattheus; Christoph Wanner; Bernard Zinman; Javed Butler
Journal:  Diabetes Obes Metab       Date:  2021-10-07       Impact factor: 6.408

Review 2.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

3.  Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Muthiah Vaduganathan; Brian L Claggett; Stephen P Juraschek; Scott D Solomon
Journal:  JAMA Cardiol       Date:  2020-05-01       Impact factor: 14.676

4.  Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Authors:  Takayoshi Kanie; Atsushi Mizuno; Yoshimitsu Takaoka; Takahiro Suzuki; Daisuke Yoneoka; Yuri Nishikawa; Wilson Wai San Tam; Jakub Morze; Andrzej Rynkiewicz; Yiqiao Xin; Olivia Wu; Rui Providencia; Joey Sw Kwong
Journal:  Cochrane Database Syst Rev       Date:  2021-10-25

5.  Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort Data.

Authors:  Brandon K Bellows; Yiyi Zhang; Zugui Zhang; Donald M Lloyd-Jones; Adam P Bress; Jordan B King; Paul Kolm; William C Cushman; Karen C Johnson; Leonardo Tamariz; Elizabeth C Oelsner; Steven Shea; Anne B Newman; Diane G Ives; David Couper; Andrew E Moran; William S Weintraub
Journal:  J Am Heart Assoc       Date:  2021-05-06       Impact factor: 5.501

6.  Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes.

Authors:  Hiroyuki Ito; Suzuko Matsumoto; Takuma Izutsu; Eiji Kusano; Shinya Nishio; Shinichi Antoku; Tomoko Yamasaki; Toshiko Mori; Michiko Togane; Shigenori Ando; Emiko Tsugami
Journal:  Diabetes Metab Syndr Obes       Date:  2019-09-09       Impact factor: 3.168

7.  Medicaid Expansion and Utilization of Antihyperglycemic Therapies.

Authors:  Andrew Sumarsono; Leo F Buckley; Sara R Machado; Rishi K Wadhera; Haider J Warraich; Rishi J Desai; Brendan M Everett; Darren K McGuire; Gregg C Fonarow; Javed Butler; Ambarish Pandey; Muthiah Vaduganathan
Journal:  Diabetes Care       Date:  2020-09-04       Impact factor: 19.112

8.  Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.

Authors:  Kieran F Docherty; Pardeep S Jhund; Brian Claggett; João Pedro Ferreira; Olof Bengtsson; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; John J V McMurray
Journal:  JAMA Cardiol       Date:  2021-11-01       Impact factor: 30.154

9.  Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.

Authors:  Ona Kinduryte Schorling; Douglas Clark; Isabella Zwiener; Stefan Kaspers; Jisoo Lee; Hristo Iliev
Journal:  Adv Ther       Date:  2020-05-05       Impact factor: 3.845

Review 10.  Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?

Authors:  Francesco Giorgino; Jiten Vora; Peter Fenici; Anna Solini
Journal:  Diabetes Obes Metab       Date:  2020-05-07       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.